Appendix B: Panel Roster and Financial Disclosures
Hepatitis C Virus
| Member | Institution | Financial Disclosure | |
|---|---|---|---|
| Company | Relationship | ||
| Meena Bansal | Icahn School of Medicine at Mount Sinai | None | N/A |
| Arthur Kim | Harvard Medical School | Kintor Pharmaceuticals | Data Monitoring Committee |
| Nina Kim | University of Washington School of Medicine and School of Public Health | Gilead FOCUS grant | Research Support (paid to institution) |
| Susanna Naggie | Duke University School of Medicine | Vir Biotechnology | Equity Interest |
| Vir Biotechnology Bio Marin Theratechnologies |
Scientific Advisor Board | ||
| AbbVie Gilead Sciences |
Research Support (paid to institution) | ||
| FHI360 PRA/BMS |
Adjudication Committee | ||
| Mark Sulkowski | Johns Hopkins University School of Medicine | Arbutus Assembly Bio Atea Antios Therapeutics AbbVie Gilead Sciences Virion |
Scientific Advisory Board |
| AbbVie Assembly Bio Gilead Sciences Janssen Contrafect EigerBio |
Research Support (paid to institution) | ||
| Merceditas Villanueva | Yale University School of Medicine | None | N/A |
| David Wyles* | Denver Health Medical Center and University of Colorado Denver School of Medicine | Gilead Sciences | Research Support (paid to institution) |
| * Section Group Lead Note: Members are required to update disclosures annually and to notify guideline staff of any relevant changes in status during the interim. |
|||
Download Guidelines
- Section Only PDF (35.94 KB)
- Full Guideline PDF (6 MB)
- Tables Only PDF (928.12 KB)